Gilead lowers US state programme price for HIV combo Stribild after public criticism
This article was originally published in Scrip
Executive Summary
The ADAP Crisis Task Force (ACTF) has negotiated a price reduction on behalf of US state AIDS Drug Assistance Programs (ADAPs) for Gilead Sciences' new four-in-one HIV drug Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate), after patient advocates balked at the annual $28,500 wholesale price set by the Foster City, California-based company.